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Abstract
Organ transplantation can be considered as replacement therapy for
patients with end-stage organ failure. The percent of one-year allograft
survival has increased due, among other factors, to a better under-
standing of the rejection process and new immunosuppressive drugs.
Immunosuppressive therapy used in transplantation prevents activa-
tion and proliferation of alloreactive T lymphocytes, although not
fully preventing chronic rejection. Recognition by recipient T cells of
alloantigens expressed by donor tissues initiates immune destruction
of allogeneic transplants. However, there is controversy concerning
the relative contribution of CD4+ and CD8+ T cells to allograft
rejection. Some animal models indicate that there is an absolute
requirement for CD4+ T cells in allogeneic rejection, whereas in others
CD4-depleted mice reject certain types of allografts. Moreover, there
is evidence that CD8+ T cells are more resistant to immunotherapy and
tolerance induction protocols. An intense focal infiltration of mainly
CD8+CTLA4+ T lymphocytes during kidney rejection has been de-
scribed in patients. This suggests that CD8+ T cells could escape from
immunosuppression and participate in the rejection process. Our
group is primarily interested in the immune mechanisms involved in
allograft rejection. Thus, we believe that a better understanding of the
role of CD8+ T cells in allograft rejection could indicate new targets
for immunotherapy in transplantation. Therefore, the objective of the
present review was to focus on the role of the CD8+ T cell population
in the rejection of allogeneic tissue.
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CD8 as a co-receptor/accessory
molecule
T lymphocytes can be separated into two
subsets based on their expression of the CD4
and CD8 molecules on the cell surface. Ap-
proximately 65% of peripheral ß-positive T
cells express CD4 and 35% express CD8.
CD4+ T cells are restricted to major histo-
compatibility complex (MHC) class II and
act as helper cells for various immune re-
sponses, whereas CD8+ T cells recognize
antigens in the context of MHC class I and
develop into cytotoxic effector cells. The
present data support the view that T cell
activation requires CD8 or CD4 and T cell
receptor (TCR) binding to the same peptide/
MHC (pMHC) molecule, leading to the clas-
sification of these cells as co-receptors. CD8
is expressed on the cell surface in two forms:
a CD8ß heterodimer and a CD8 homo-
dimer. CD8ß is the prevalent form on the
surfaces of the T cell population and is be-
lieved to enhance cytotoxic T lymphocyte
(CTL) activation better than CD8. CD8,
either  or ß chain, consists of four discrete
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functional domains that can be related to the
primary sequence as follows: the Ig-like
ectodomains, the membrane proximal stalk
region, the transmembrane domain, and the
cytoplasmic domain. The extracellular Ig-
like domain is involved in the binding to
MHC. The stalk region is flexible and highly
glycosylated, a fact which is believed to be
important in extending the region to reach
the MHC, and is also postulated to interact
with TCR. The cytoplasmic domain of CD8
consists of a p56lck binding motif important
for signal transduction.
CD8 enhances T cell recognition of
pMHC on the surface of antigen-presenting
cells (APC) since binding of CD8 and TCR
to the same pMHC would increase the over-
all avidity between the surfaces of APC and
T cells. Second, CD8 binding to pMHC re-
cruits p56lck tyrosine kinase through its cyto-
plasmic domain into the T cell signaling
complex and thus enhances signal transduc-
tion. Third, CD8 binding to pMHC possibly
reduces the overall flexibility of pMHC on
the cell surface, positioning the pMHC more
favorably for TCR binding. It is more likely
that CD8 is recruited to the pMHC-TCR
complex by intracellular binding of the 
chain-associated p56lck to TCR-associated
ZAP-70. Once recruited, CD8 would en-
hance pMHC binding by adding to the much
stronger TCR-pMHC interaction (1).
The term accessory molecule has been
used to describe the activities of CD4 and
CD8 when they are unable to bind to the
same MHC molecule as the TCR. There are
conflicting data as to whether the binding of
MHC molecules in an accessory manner
contributes to T cell activation. However,
Smith and Potter (2) showed that transgenic
mouse skin grafts expressing a disparate class
I molecule that does not engage CD8 are
rejected as vigorously as wild-type grafts.
Rejection was caused by a CD8+ class I
reactive CTL, which required CD8 engage-
ment for cytolysis and secretion of inter-
feron  (IFN-), although the co-engagement
with the same MHC class I molecule as TCR
was not necessary. As an accessory mole-
cule, CD8 would increase the overall avidity
of the T cell-target cell interaction, or trans-
duce signals through p56lck that either act
independently of or intersect downstream
from TCR-mediated signal transduction.
CD8+ T cells and allograft rejection
The previous belief that CD8+ T cells are
a homogenous population of CD4-depend-
ent cells and produce a limited number of
cytokines such as IFN-, tumor necrosis fac-
tor (TNF-) and lymphotoxin has changed.
It is now accepted that CD8+ T cells can
polarize in the same way as CD4+ T cells into
cytotoxic T (Tc) cells - Tc1 (IFN-) and Tc2
(IL-4, IL-5) - and in some situations CD4-
independent responses by CD8+ T cells oc-
cur. CD8+ T cell helper independence might
be related to the avidity of the interaction
between TCR on these cells and the antigen
presented by class I molecules on the APC.
High avidity T cells (multiple interactions of
TCR and CD8 molecules on the T cell with
pMHC complexes on the APC) may receive
a strong signal that induces both IL-2R and
IL-2 synthesis resulting in a helper-inde-
pendent response. CD8+ T cells with low
avidity may induce IL-2R but produce little
or no IL-2 and depend on IL-2 production by
CD4+ T cells. Heath et al. (3), using trans-
genic mice expressing a specific TCR for H-
2Kb, showed that TCRhigh/CD8high cells tested
against splenocytes expressing different den-
sities of H-2Kb were competent IL-2 produc-
ers, whereas TCRlow/CD8low presented mar-
ginal or no levels of IL-2 in the same assay.
Deeths et al. (4) showed that in vitro a helper-
independent phase of the CD8+ T cell re-
sponse is consistent with the ability of these
cells to support their own expansion by pro-
ducing IL-2 in response to co-stimulation
provided by CD28 binding to B7 ligands,
leukocyte function accessory-1 molecule
(LFA-1) binding to intercellular adhesion
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molecule-1 (ICAM-1), and possibly other
co-stimulatory receptors binding to their
ligands.
In transplantation it has been shown that
CD4+ T cell effector function is sufficient to
mediate allograft failure, and it has been
suggested that CD8+ T cell-mediated effects
are dependent on CD4+ T cell help. Thus,
whether CD8+ T cells are sufficient to reject
allografts or play an additive role in the
progression of the rejection process has not
been settled as yet. In heart-transplanted pa-
tients, the presence of CD69+/CD8+ cells in
peripheral blood exceeding 15% of all T
cells is correlated with vigorous rejection
(5). CD8+ T cells infiltrating the myocardi-
um of patients in heart allograft rejection (6)
displayed an activated CD69+ phenotype with
perforin activity. Moreover, Delfs et al. (7)
showed in RAG-/- mice that, in the absence
of T and B cells, a cardiac allograft survives
indefinitely whereas the adoptive transfer of
reactive Tc cells caused alterations compat-
ible with rejection. Recipients injected with
Tc1 cells (IFN-high) showed graft vasculitis
and arteriopathy and recipients injected with
Tc2 cells (IL-4high/IL-5high) presented exten-
sive eosinophil infiltration. Gilot et al. (8)
showed that during a heart rejection episode
in mice the graft-infiltrating antigen-specific
CD8+ T cell population expanded with modu-
lation of surface markers such as CD62L and
CD69 besides production of IFN-. Jones et
al. (9) showed that in mice depleted of T
cells (thymectomy, anti-CD4, anti-CD8), the
injection of 6 x 106 TCR antigen-specific
CD8+ T cells was sufficient to promote re-
jection of a fully mismatched cardiac al-
lograft. CD8+ T cells appeared in the spleen
and lymph nodes 7 days after transplanta-
tion. These cells divided, were blastic and
up-regulated CD44/CD69 and down-regu-
lated CD45RB/CD62L. Bishop et al. (10)
showed that IFN--deficient mice treated with
anti-CD4 rejected a cardiac allograft through
an unusual CD8-mediated, CD4-independ-
ent mechanism of allograft rejection. Fur-
thermore, rejection was resistant to treat-
ment with anti-CD154 and was associated
with IL-4 production and eosinophil influx
into the graft. Therefore, although it has
been accepted that CD4+ T cells may play a
crucial role in allograft rejection there is
evidence in certain situations that CD4 help
is not always required to generate CD8+
CTL.
Results from mouse models of transplan-
tation indicate that intrinsic features of the
transplanted tissue primarily dictate the con-
tribution of CD4+ and CD8+ T cell subsets to
graft rejection. For instance, it has been
shown that islets are more susceptible to
CD8-mediated rejection. CD8 absence ei-
ther in donors (11,12), i.e., by using islets
from CD8-deficient mice (ß2-microglobu-
lin-/-) or using monoclonal antibody directed
against MHC class I, or recipients (13)
possessing no CD8+ T cells (ß2-microglobu-
lin-/-) improved islet allograft survival.
Haskova et al. (14) used CD4- or CD8-
deficient knockout mice to investigate the
role of T cell subsets in allograft rejection.
The results showed that CD4+ T cells play a
critical role in the rejection of corneal allo-
grafts, whereas CD8+ T cells appear to be
involved in the rejection of skin allografts.
Boisgérault et al. (15) showed that both CD4+
and CD8+ T cells play a role during corneal
allograft rejection. Mice rejecting corneal
allografts mount a potent T cell response
associated with the activation of IL-2-pro-
ducing CD4+ and IFN--producing CD8+
alloreactive T cells. Cardiac allografts are
rejected by both CD4+ and CD8+ T cells but
it seems that CD4 is mandatory to initiate the
rejection of this tissue. Wiseman et al. (16)
used the adoptive transfer of CD4+ T cells
into recipients deficient in B and CD8+ T
cells to investigate the role of CD4+ T cells in
cardiac allograft. Rejection occurred in a
normal fashion in hearts from wild-type do-
nors, demonstrating that CD4+ T cells are
sufficient to promote cardiac allograft rejec-
tion in the absence of CD8 and B cells.
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Fischbein et al. (17) showed that intimal
lesions were absent in hearts transplanted
into nude and CD4-/- knockout mice. In
contrast, donor hearts in CD8-/- knockout
mice developed cardiac allograft vasculo-
pathy, although significantly less than in
wild-type mice. Adoptive transfer of T lym-
phocyte subset populations into nude recipi-
ents confirmed that cardiac allograft vascu-
lopathy was absolutely contingent on CD4+
lymphocytes, and that CD8+ lymphocytes
played an additive role in intimal progres-
sion. Although CD8+ lymphocytes alone did
not cause cardiac allograft vasculopathy, the
results suggested that both CD4+ and CD8+
lymphocytes contribute to the progression of
intimal lesion development via secretion of
IFN-. Ogura et al. (18) used a monoclonal
antibody directed against CD8+ T cells to
investigate the immune response after a liver
transplantation in the absence of the CD8
population. Histologic findings indicated that
severe acute rejection and cell-mediated tox-
icity factors such as granzyme B and Fas
ligand (FasL) were still evident, albeit at
lower levels. These results indicate that cells
other than CD8+ T cells express cytotoxic
mediators in rejecting allograft.
CD8+ T cells and cytokines/
chemokines
A review by Hamann et al. (19) reports
that up- and down-regulation of surface mark-
ers, mediators of cytotoxicity and cytokine
production occurs in humans during the dif-
ferentiation of CD8+ T cells, which permits
to classify them as naive, memory and effec-
tor cells. However, most of the studies were
performed during viral infection and could
not reflect a transplant situation. During an
infection, human effector CD8+ T cells ex-
press markers of cytotoxicity and cell death
such as perforin, granzyme B, Fas and FasL.
IFN- and TNF- are the growth factors
produced by these cells after activation.
Memory CD8+ T cells express higher levels
of Fas but lower levels of FasL. Perforin and
granzyme B are also expressed at lower lev-
els than in effector CD8+ T cells. IL-2 and
IL-4 are produced by memory cells and the
levels of IFN- and TNF- are similar to
those seen in the effector subpopulation.
Antigen-triggered T cell activation and
the subsequent infiltration of activated CD4+,
CD8+, macrophages, and natural killer (NK)
cells into the graft are key events in acute
allograft rejection. CTLs include CD4+ and
CD8+ cells with the ability to secrete cyto-
toxic cytokines such as TNF- and IFN- in
the region of their targets. The potential
mechanism of CTL involvement in acute
allograft rejection is mediated by cytotoxic
granule-based killing by perforin and gran-
zyme B- or FasL-induced programmed cell
death. It has been suggested that CD8+ cyto-
toxic lymphocytes depend primarily on the
perforin/granzyme system to kill their tar-
gets, whereas CD4+ T cells utilize the FasL
to induce cell death. The presence of acti-
vated CTLs and expression of kill mediators
have been described in acute rejection of
human hearts, lungs and kidneys (20,21).
In the allograft response, several studies
have pointed out CD8+ T cell as the major
effector cells and in addition to their cyto-
toxic effector function, activated CD8+ T
cells also have the ability to produce high
levels of proinflammatory cytokines includ-
ing IFN-. This cytokine has been shown to
up-regulate the expression of MHC mol-
ecules and to enhance alloantigen presenta-
tion on target tissues; IFN- also serves to
enhance inflammation and stimulate non-
specific effector cells such as macrophages
and NK cells (22,23). There is considerable
evidence of increased intragraft expression
of IFN- during rejection of experimental
cardiac, renal and islet transplants. Diamond
and Gill (22) showed that diabetes induction
in SCID mice, which lack functional B and T
cells, is reversible by islet transplant. How-
ever, the transfer of in vitro-primed alloreac-
tive CD8+ T cells caused islet allograft rejec-
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tion without requiring perforin, being only
partially dependent on FasL production but
completely dependent of IFN- production,
suggesting that in the absence of CD4+ T
cells, IFN- contributes to differentiation and/
or expansion of effector CD8+ T cells. Ex-
pression of cytotoxic attack molecules (gran-
zyme B and perforin) has been identified in
human renal allograft biopsies by RT-PCR.
In addition, granzyme B, IL-2 and IFN-
mRNA expression has being correlated with
acute rejection (24).
CD8+ T cells and IFN- could have other
functions during allograft rejection, as was
shown by Braun et al. (25) through a cardiac
transplant in mice where synthesis of IFN-
by CD8+ T cells inhibits IL-5 production and
consequently intragraft eosinophilia. Deple-
tion of anti-CD8 cells in recipient mice prior
to cardiac transplantation induced intragraft
IL-5-dependent eosinophilia.
Not only cytokines but also chemokines
play a role in transplantation due to their
ability to attract cells to the inflammatory
site. These factors are stored in the cytolytic
granules of CD8+ CTLs and can be secreted
by these cells as preformed and prepacked
chemokines (26). Acute allograft rejection is
characterized by an intense cellular immune
response marked by influx of circulating
leukocytes into the transplant. The accumu-
lation of activated immune cells in the al-
lograft is essential for the pathogenesis of
tissue injury. Recruitment of leukocytes into
sites of inflammation involves a tightly regu-
lated series of molecular interactions that
includes the initial capture and rolling of
cells mediated by selectins, followed by firm
arrest on the endothelium, a process medi-
ated by integrins. In the course of these
events, the leukocyte becomes activated
through stimulation of G protein-coupled
chemokine receptors, resulting in enhanced
integrin adhesiveness and activation-depend-
ent stable arrest. In addition, specific chemo-
kines may amplify tissue inflammation by
stimulating neutrophil degranulation and
monocyte superoxide production.
Kapoor et al. (27) showed that CD8+ T
cells were responsible for the early expres-
sion of IP-10 and Mig chemokines in mouse
cardiac allografts. These chemokines are de-
pendent on the presence of IFN- since in
IFN--/- recipients IP-10 and Mig were com-
pletely absent. They are likely to mediate the
recruitment of neutrophils, macrophages and
NK cells into the graft during the transplant-
induced wound healing. After stimulation,
CD8+ T cells would produce IFN- and in-
duce expression of these chemokines in the
allograft (28,29).
Skin transplantation in mice (29) pre-
sented an early IP-10 expression (iso- and
allografts) which decreased by day 7, with
high levels occurring in the allografts only at
9 days post-transplant. Expression of Mig
reached high levels in allografts only 9 days
after transplantation. Intragraft expression
of RANTES was also undetectable until day
9 when low levels were detected. In CD8-
mediated rejection, anti-CD4 monoclonal
antibody-treated mice presented a delay in
skin rejection (20 days), with an intragraft
expression of Mig and IP-10 undetectable
until day 9 but expressed at high levels on
day 18. RANTES expression was detectable
at high levels during rejection (starting on
day 18).
Fractalkine and CXCR3 (induced by
IFN-) are chemokines that interact with
CX3CR1 to affect firm adhesion of resting
and activated CD8+ T lymphocytes, mono-
cytes and NK cells. CX3CR1 is predomi-
nantly expressed by activated Th1, CD8+
and NK cells, and its expression is regulated
by cytokines like IL-2. In a cardiac allograft
model, Robinson et al. (30) showed that
recipient treatment with anti-CX3CR1 caused
an increase in graft survival.
Fahy et al. (31) used a model of SCID
mice reconstituted with human peripheral
blood mononuclear cells, submitted to hu-
man skin transplant and injected with sev-
eral chemokines to address the migration of
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human leukocytes in vivo. Monocyte-derived
chemokine had a predominant effect on re-
cruitment of CD8 T+ cells, inducing a mod-
erate increase in the number of CCR4+ cells
and a slight increase in CCR3+ cells besides
IL-5-secreting cells.
CD8+ T cells and endothelium
Chronic rejection of cardiac allografts is
responsible for 23 to 36% of deaths after the
first year of transplant and is characterized
by a diffuse, concentric intimal proliferative
response within the arteries of transplanted
organs. To date, chronic rejection seems to
initiate after the allorecognition of graft en-
dothelium with subsequent leukocyte infil-
tration and production of cytokines, chemo-
kines, and growth factors. In response, vas-
cular smooth muscle cells are thought to
transmigrate to the intimal compartment re-
sulting in occlusive lesion formation.
CTLs (32) reactive with endothelium have
been proposed to be the effectors of cell-
mediated vascular rejection, a potential pre-
cursor lesion of chronic graft rejection. En-
dothelial cell-selective CTLs have been iso-
lated from endomyocardial biopsies of
acutely rejected heart transplants. It has been
shown that endothelial cell-stimulated CTL
clones present low production of IFN- and
constitutive expression of CD40L, a mole-
cule that is not usually seen on CD8+ T cells.
Endothelial cells have been proposed to be a
semiprofessional APC of intermediate stimu-
latory capacity. This suggests a predomi-
nantly modulatory role for the endothelium
that might be inhibitory for immune-medi-
ated injury. Endothelial cell-selective CTLs
could develop a specific endothelial rejec-
tion independently of widespread parenchy-
mal rejection. Using flow cytometry, Dengler
et al. (33) showed that in endothelial cell-
stimulated CTL cultures there was a lower
frequency of reactive precursors and clonal
expansion than in conventional CTL cultures
in spite of perforin and IFN- detection.
Légaré et al. (34) showed that in an aortic
transplant model, the loss of medial smooth
muscle cells was associated with CD8+ T
cells. The use of anti-CD8 monoclonal anti-
body reduced CD8+ T cell counts in periph-
eral blood, reduced medial smooth muscle
cell apoptosis at 20 days and increased
smooth muscle cell counts at 60 days. Using
PCR, the group showed an up-regulation of
CD8+ T cell mediators of apoptosis (perforin,
granzyme B, FasL).
CD8+ T cells and immunosuppressive
therapy
CD8+ T cells seem to be less affected by
most of the immunosuppressive therapies
used to prevent rejection than CD4+ T cells.
For instance, it has been proposed that CD8+
T cells are not dependent on co-stimulation
provided by the CD40L-CD40 pathway (35-
38). In addition, only some of these cells
express CD40L. In models of skin and small
bowel allografts the rejection seems to occur
despite the CD28 and/or CD40L pathways
and is mediated by alloreactive CD8+ T cells
(35,39).
In a model of aorta transplant in mice
(36) it was shown that anti-CD40L and anti-
CD4 therapy could delay but not prevent the
graft from developing transplant arterioscle-
rosis. Anti-CD8 antibody caused a decrease
in IL-12 and IFN- expression and a de-
crease in macrophage infiltration and induc-
ible nitric oxide synthase. However, increased
expression of IL-4 was observed within the
graft, which in turn may be responsible for
the development of transplant arteriosclero-
sis in the long term. Moreover, treatment
with both anti-CD8 and MR1 (anti-CD40L)
resulted in a significant reduction of intimal
proliferation in sections of the cardiac al-
lograft at day 30 but by day 50 the allograft
began to exhibit progressive intimal prolif-
eration (37). Thus, subsets of CD8+ T cells
present in the repertoire may be differen-
tially susceptible to targeting via CD40-
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CD40L interaction. Using a cardiac model in
mice and the adoptive transfer of a TCR
antigen-specific CD8+ T cell population,
Jones et al. (38) showed that CD4+ T cell-
mediated rejection is prevented by anti-
CD40L monoclonal antibody but that CD8+
T cells remain fully functional. Blocking
CD40L interaction had no effect on CD8+ T
cell activation, proliferation, differentiation,
homing to the target allograft or cytokine
production. Rothstein et al. (35) showed that
rejection of islets or skin in mice was pre-
vented or delayed by the combined blockade
of CD45RB and CD40L molecules, respec-
tively, whereas either agent used alone was
not efficient. Combined blockade inhibited
CD8 infiltration and caused a decrease in
CD8 cells in lymph nodes, suggesting that
anti-CD45RB may affect CD8 homing to
lymph nodes or induce partial depletion of
this T cell subset.
In a skin model, Trambley et al. (40)
showed that co-stimulation blockade (CD40
and CD28) combined with anti-asialo GM1
antibodies delayed allograft rejection by in-
hibition of CD8-dependent rejection since
20% of CD8+ T cells express asialo GM1.
Recipients treated with co-stimulation block-
ade and CD8+ T cell depletion had markedly
prolonged allograft survival. In addition,
RAG-/- mice reconstituted with CD8+ T cells
and treated with anti-asialo GM1 showed
increased allograft survival with very few
CD8+ T cells undergoing division.
Concerning immunosuppressive drugs
(41), it has been proposed that in mice CD8+
T cells require a higher dose of cyclosporin
A or FK506 than CD4+ T cells to become
susceptible. van Hoffen et al. (42), using
heart biopsies from transplanted patients on
an immunosuppressive regimen showed that
macrophages, CD4 and CD8 (2:1 ratio) cells
were infiltrating the graft. Co-stimulatory
molecules such as CD28, CD40 or CTLA4
were expressed at low levels, possibly repre-
senting chronic activation of T cells instead
of anergy. CD4+ T cells presented a higher
percentage of apoptosis (65%) than CD8+ T
cells (26%), suggesting that the presence of
CD8 could contribute to the ongoing rejec-
tion process.
Chen et al. (43), using a cardiac trans-
plant in mice and the injection of TCR anti-
gen-specific CD8+ T cells, showed that the
use of rapamycin for immunosuppressive
therapy, although promoting indefinite graft
survival, had no effect on the up-regulation
of CD44/CD25 surface markers. Using hu-
man blood lymphocytes, Slavik et al. (44)
showed that CD8+ T cells could proliferate
even in the presence of rapamycin when
activated by TCR cross-linking ex vivo or of
some CD8+ T cell clones. The results sug-
gested that both the strength of the signal
delivered through the TCR and secondary
co-stimulatory signals determine whether
rapamycin inhibits or enhances the clonal
expansion of CD8+ T cells.
CD8+ T cells and suppression
In the 1970’s Gershon proposed the pos-
sibility of a suppressor CD8+ T cell popula-
tion based on an in vitro assay (45). The
inability to clone such cells with an antigen
or to show evidence for CD8+ T cell immu-
noregulation in vivo created new questions
about tolerance.
Cobbold and Waldmann (46), using an
anti-CD4 monoclonal antibody in mice sub-
mitted to transplant, showed that it is pos-
sible to develop a powerful form of immune
regulation that acts to suppress any naive or
primed CD4+ or CD8+ T cells against the
same antigen. Thus, a tolerant immune sys-
tem is maintained by a population of CD4+ T
cells that act to suppress the generation of
any effector cell in response to the same
antigen or to different antigens expressed on
the same APC. Although CD4+ T cells seem
to be unique in the process of tolerance
induction, it has been possible to generate a
regulatory population of CD8+CD28- T cells
in vitro (47). Moreover, recently a popula-
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tion of CD8+CD28- T cells (Ts) was isolated
from peripheral blood of renal, cardiac and
liver transplanted patients and its ability to
inhibit the up-regulation of CD80 and CD86
expression by donor APC in culture was
shown by Ciubotariu et al. (48). During re-
jection episodes, patients did not present the
suppressor (Ts) population, whereas rejec-
tion-free patients presented Ts with the sup-
pressor activity specific for the donor’s HLA
class I antigens.
Zhang et al. (49) identified a new subset
of antigen-specific regulatory double nega-
tive T cells able to suppress in vitro re-
sponses and enhance donor-specific skin al-
lograft survival. This suppression required
direct contact with activated CD8+ T cells,
promoting apoptosis of these cells through
the Fas-FasL pathway.
Vukmanovic-Stejic et al. (50) reported in
their review the possibility of CD8+ T cell-
inducing modulation as these cells can se-
crete potent immunoregulatory cytokines
such as IL-4, IL-10 and transforming growth
factor ß (TGF-ß). They suggested that the
immunoregulatory effects of this cell popu-
lation could be mediated by direct lysis or
apoptosis induction in specific CD4+ T cell
targets or by modifying the behavior of APC.
Moreover, Vignes et al. (51) reported that an
immunoregulatory population of CD8+ T
cells arose in rats submitted to cardiac trans-
plantation due to a donor-specific transfu-
sion before transplantation. Increased graft
survival was associated with the production
of the suppressive cytokine TGF-ß1 and the
inhibition of Th1- and Th2-related cytokine
expression.
In a model of kidney transplant in rats,
Zhou et al. (52) showed that oral administra-
tion of donor splenocytes increased allograft
survival in a fully mismatched combination.
Graft infiltrating cells in non-rejected kid-
neys presented a reduction of the CD4+ T
cell population, whereas the percentage of
CD8+ T cells did not change. Although it was
possible to detect mRNA for granzyme B,
perforin and FasL besides IFN- and TGF-ß,
confirming that CD8+ T cells in the graft
infiltrating cells were alloresponsive CTLs,
adoptive transfer of CD8+ T cells (graft infil-
trating cells) to naive rats significantly im-
proved allograft survival, whereas CD4+ T
cells did not. Moreover, detection of IL-4
mRNA suggested that these cells were Tc2
deviated and potentially regulatory.
In conclusion, these controversial results
suggest that CD8+ regulatory cells might be
sufficient for, but not essential to, the devel-
opment of tolerance.
CD8+ T cells and indirect/direct
antigen presentation
Recipient T cell recognition of donor
intact allo-MHC molecules (+peptide) pre-
sented on both the allograft itself and on
donor passenger leukocytes has been termed
direct pathway. Peptides derived from allo-
geneic MHC molecules and presented by
recipient APC to recipient T cells are termed
indirect pathway.
In animal models, the direct pathway has
been estimated to represent >90% of the T
cell repertoire participating in the process of
acute rejection, whereas the indirect path-
way would include only 1-10% (53). T cell
responses occurring via direct allorecogni-
tion play a critical role during the early phase
of acute graft rejection by sensitizing the
host to graft antigens. However, it has been
suggested (54) that the indirect pathway plays
a critical role in the development and pro-
gression of chronic rejection. In addition,
while the direct alloresponse is highly sensi-
tive to treatment with immunosuppressive
drugs including cyclosporin A, indirect allo-
recognition is thought to be poorly sensitive
to blockade with cyclosporin A.
After transplantation, over time the do-
nor passenger leukocytes are washed out
from allografts, whereas recipient APC con-
tinually infiltrate the allograft and process/
present shed donor allopeptides. This pro-
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cess results in the diminishing importance of
the alloresponse mediated by directly primed
T cells and suggests that the indirect path-
way represents the driving force in the actual
destruction of transplanted tissues. More-
over, T cells from renal, cardiac and lung
transplant recipients with chronic rejection
show evidence of reactivity to donor HLA
allopeptides and patients with cardiac al-
lograft vasculopathy show evidence of do-
nor-specific hyporesponsiveness to directly
presented but not indirectly presented donor
HLA antigens.
Lee et al. (54), using mice submitted to
heart transplantation, showed that indirect
allorecognition plays a major role in the
pathogenesis of chronic cardiac allograft vas-
culopathy mainly through IFN- production
by CD4+ T cells. CD4+ T cells reactive via
the indirect pathway could initiate chronic
rejection by facilitating either alloantibody
production or CD8+ T cell effector func-
tions. Valujskikh et al. (55), using a model of
mouse skin transplantation, showed that in-
direct recognition by CD4+ and CD8+ T cells
occurs when donor and recipient are fully
mismatched for MHC. IFN- was the cy-
tokine most frequently identified by ELISPOT
both in indirect and direct priming models.
Indirectly primed CD8+ T cells were the promi-
nent component of the indirect response, com-
prising up to 3-5% of the total alloreactive
repertoire. Benichou (56) showed that, during
mouse skin allograft rejection, donor MHC
molecules are processed and presented as pep-
tides by the recipient’s APC in vivo, eliciting
CD4+ and CD8+ T cell responses which are
restricted to the recipient’s own MHC mol-
ecules.
Future prospects
Although controversy still remains con-
cerning the relative contribution of CD4+
and CD8+ T cells to allograft rejection, the
important role played by CD8 as effector
cells in transplantation has been well estab-
lished. In addition, it has been shown that
CD8+ T cells can escape from the immuno-
suppressive effects of drugs such as cyclo-
sporine and rapamycin. This suggests that
these CD8+ T cells may be involved in the
development of chronic rejection. Moreover,
Wang et al. (57) showed in an experimental
model that in high numbers, primed CD8+ T
cells can provide help to naive CD8+ T cells
and promote activation of the latter.
Our group has performed kidney trans-
plants since 1976 (554 transplants only in
2001) and, as also reported by other groups,
2-3% of our allografts are lost during the first
year to irreversible acute rejection, whereas
a larger number is lost during each subse-
quent year to chronic rejection. We are now
participating in a multicenter study using
drugs such as FTY720, FK506, and RAD
amongst others and a flow cytometry assay
to evaluate the contribution of each T cell
population to allograft rejection.
Monitoring the recipient’s immune re-
sponse after transplantation has been pointed
out as crucial for the adequacy of immuno-
suppressive therapy. Also the individualiza-
tion of maintenance immunosuppressive
therapy could provide a balance between the
absence of an allogeneic specific response
and an adequate immune response against
pathogens. For both monitoring of immune
response and an individualized approach to
antirejection therapy, conditions are needed
to monitor T cell behavior after transplanta-
tion. The development of new techniques to
identify the CD8+ T cell population, its fate
and action during rejection is crucial for the
design of rational immunosuppressive thera-
py. However, few attempts have been made
to focus on new strategies to identify T cell
subsets during allograft rejection. Kusaka et
al. (58) developed a T cell clonotype analy-
sis (RT-PCR) of peripheral blood and graft
biopsies in kidney-transplanted patients with
voluntary immunosuppression withdrawal
and stable graft function for 9 years to detect
antigen-specific T cells. A high level of do-
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nor-specific CD4+-CD8+ T cell clonotypes
was found during the late tolerance pre-
rejection stage, indicating that changes in the
alloreactive T cell repertoire may be leading
indicators of chronic rejection. Benlagha et
al. (59) reported the generation and use of
tetramers to identify mouse or human T cells
restricted to MHC-like molecules (CD1d).
Altman et al. (60) showed that the use of
multimeric pMHC complexes provides a gen-
eral, rapid, and direct method for analysis of
the phenotypic state of antigen-specific T
cells. The study was done on HIV-infected
patients and was consistent with previous
estimates for anti-HIV CTL populations by
limiting dilution analysis.
Using the knowledge about the CD8 MHC
class I crystal structure, cytotoxic T cell
inhibitors have been developed and used in
infected mice (61), showing dose-dependent
inhibition of a primary allogeneic CTL assay
while having no effect on the CD4-depend-
ent mixed lymphocyte reaction. Moreover,
Choksi et al. (62) reported that the SC4
analogue of the CD8 molecule was found
to be inhibitory during both the generation
and effector stages of CTLs, and also to
significantly prolong skin allograft survival
across an MHC class I barrier. As described
above, some strategies are being developed
to identify or to deplete specific T cell popu-
lations, but although they appear promising
their potential use in transplantation still
remains to be elucidated.
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